AbbVie Inc. $ABBV Shares Sold by Montag A & Associates Inc.

Montag A & Associates Inc. cut its position in AbbVie Inc. (NYSE:ABBV) by 3.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 72,244 shares of the company’s stock after selling 2,746 shares during the period. Montag A & Associates Inc.’s holdings in AbbVie were worth $15,712,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Chelsea Counsel Co. acquired a new stake in AbbVie in the third quarter valued at $26,000. Litman Gregory Wealth Management LLC acquired a new stake in shares of AbbVie during the 4th quarter worth about $28,000. Westend Capital Management LLC purchased a new stake in AbbVie during the fourth quarter worth approximately $29,000. Imprint Wealth LLC lifted its stake in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the last quarter. Finally, Texas Capital Bancshares Inc TX acquired a new position in AbbVie in the third quarter valued at approximately $31,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Commission approved TEPKINLY (epcoritamab) plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma, making it the first and only bispecific-based therapy approved in Europe for this setting and expanding AbbVie’s oncology growth opportunity. Article Title
• Positive Sentiment: Cantor Fitzgerald raised its price target on AbbVie to $265 from $240 and reiterated an overweight rating, signaling continued analyst confidence in the stock’s outlook. Article Title
• Neutral Sentiment: Media coverage highlighted AbbVie as a high-yield dividend and “quality, low-stress” healthcare stock, which may support investor sentiment but does not change fundamentals. Article Title
• Negative Sentiment: AbbVie lowered its Q2 2026 EPS guidance to $3.57-$3.61 versus the consensus $3.77, suggesting earnings could come in below expectations. Article Title
• Negative Sentiment: The company also cut full-year 2026 EPS guidance to $13.91-$14.11, below the consensus estimate of $14.25, which may pressure the shares despite recent product wins. Article Title

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ABBV. Cantor Fitzgerald boosted their price objective on shares of AbbVie from $240.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday. Piper Sandler reissued an “overweight” rating and issued a $298.00 price target on shares of AbbVie in a research report on Tuesday, June 23rd. Guggenheim restated a “buy” rating and issued a $249.00 price objective on shares of AbbVie in a research note on Friday, May 1st. Wells Fargo & Company set a $260.00 target price on AbbVie in a research report on Monday, June 22nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Monday, June 8th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average price target of $256.67.

AbbVie Price Performance

NYSE:ABBV opened at $254.71 on Wednesday. The firm’s fifty day moving average price is $222.39 and its 200 day moving average price is $220.69. AbbVie Inc. has a 1-year low of $184.63 and a 1-year high of $261.64. The firm has a market cap of $450.02 billion, a price-to-earnings ratio of 125.47, a price-to-earnings-growth ratio of 0.84 and a beta of 0.30.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the prior year, the firm earned $2.46 EPS. AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. As a group, analysts expect that AbbVie Inc. will post 14.28 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s payout ratio is presently 340.89%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.